🇺🇸 FDA

Intelligence · Clinical Pipeline

Takeda Pipeline

All ClinicalTrials.gov programs at Takeda — phase, modality, and trial IDs.

Programs
1,179

Quick answer

Takeda has 1,179 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

  1. Namilumab

    Takeda

    Rheumatoid Arthritis

    phase 2 small molecule completed

    2 trials

  2. Ninlaro

    Takeda

    Immune Thrombocytopenia

    phase 2 small molecule terminated

    1 trial

  3. Niraparib

    Takeda

    Efficacy

    phase 2 small molecule active

    1 trial

  4. Niraparib

    Takeda

    Ovarian Cancer

    phase 2 small molecule completed

    2 trials

  5. Niraparib-Bevacizumab

    Takeda

    Platinum-sensitive Recurrent Ovarian Cancer Patients Previously Treated With a PARP Inhibitor

    phase 2 small molecule active

    1 trial

  6. Nivolumab

    Takeda

    Relapsed Multiple Myeloma

    phase 2 small molecule terminated

    1 trial

  7. NoV GI.1/GII.4 Bivalent VLP Vaccine

    Takeda

    Norovirus

    phase 2 mab completed

    1 trial

  8. NoV Placebo-matching Saline

    Takeda

    Healthy Volunteers

    phase 2 mab completed

    1 trial

  9. NoV Vaccine

    Takeda

    Healthy Volunteers

    phase 2 mab completed

    1 trial

  10. Norovirus Bivalent VLP Vaccine

    Takeda

    Norovirus Prevention

    phase 2 mab completed

    1 trial

  11. Norovirus Bivalent Vaccine

    Takeda

    Prevention From Norovirus Infection

    phase 2 mab completed

    1 trial

  12. Norovirus GI.1/GII.4 Bivalent VLP Vaccine

    Takeda

    Norovirus

    phase 2 mab completed

    1 trial

  13. Norwalk VLP vaccine

    Takeda

    Acute Gastroenteritis

    phase 2 mab completed

    1 trial

  14. Ondansetron

    Takeda

    Nausea

    phase 2 small molecule completed

    1 trial

  15. Oral Budesonide Suspension (MB-9)

    Takeda

    Eosinophilic Esophagitis (EoE)

    phase 2 small molecule completed

    1 trial

  16. Orteronel 300mg BID

    Takeda

    Metastatic or Advanced Non-resectable Granulosa Cell Ovarian Tumors

    phase 2 small molecule terminated

    1 trial

  17. PF-00547659

    Takeda

    Crohn's Disease

    phase 2 small molecule completed

    1 trial

  18. PF-00547659 SC injection

    Takeda

    Crohn's Disease

    phase 2 small molecule completed

    1 trial

  19. PVS-10200

    Takeda

    Peripheral Artery Disease

    phase 2 mab completed

    1 trial

  20. Paclitaxel

    Takeda

    Endometrial Neoplasms

    phase 2 small molecule completed

    1 trial

  21. Paclitaxel

    Takeda

    Ovarian Cancer

    phase 2 small molecule completed

    1 trial

  22. Paclitaxel and TAK-228

    Takeda

    Metastatic Urothelial Cancer

    phase 2 other active

    1 trial

  23. Pacritinib

    Takeda

    Primary Myelofibrosis

    phase 2 mab terminated

    1 trial

  24. Panitumumab

    Takeda

    Squamous Cell Carcinoma of Head and Neck

    phase 2 small molecule completed

    1 trial

  25. Panitumumab + TAS-102

    Takeda

    Colorectal Cancer

    phase 2 small molecule completed

    1 trial

  26. Pevonedistat

    Takeda

    Acute Myeloid Leukemia (AML)

    phase 2 small molecule completed

    2 trials

  27. Pevonedistat

    Takeda

    Myelodysplastic Syndromes (MDS)

    phase 2 small molecule terminated

    1 trial

  28. Pioglitazone

    Takeda

    Oxidative Stress

    phase 2 small molecule completed

    1 trial

  29. Pioglitazone

    Takeda

    Inflammation

    phase 2 small molecule completed

    1 trial

  30. Pioglitazone

    Takeda

    Depressive Disorder, Major

    phase 2 small molecule completed

    1 trial

  31. Pioglitazone

    Takeda

    Chronic Pancreatitis

    phase 2 small molecule completed

    1 trial

  32. Pioglitazone and atorvastatin

    Takeda

    Cardiovascular Diseases

    phase 2 small molecule completed

    1 trial

  33. Pioglitazone and azilsartan

    Takeda

    Diabetes Mellitus

    phase 2 small molecule completed

    1 trial

  34. Placebo

    Takeda

    Ulcerative Colitis

    phase 2 small molecule completed

    1 trial

  35. Placebo

    Takeda

    Primary Immune Thrombocytopenia

    phase 2 small molecule completed

    1 trial

  36. Placebo

    Takeda

    Celiac Disease

    phase 2 small molecule completed

    1 trial

  37. Placebo

    Takeda

    Gout

    phase 2 small molecule completed

    1 trial

  38. Placebo

    Takeda

    Endometriosis

    phase 2 small molecule completed

    2 trials

  39. Placebo

    Takeda

    Graft Rejection

    phase 2 mab completed

    1 trial

  40. Placebo

    Takeda

    Narcolepsy Type 2

    phase 2 small molecule completed

    1 trial

  41. Placebo

    Takeda

    Essential Hypertension

    phase 2 small molecule completed

    1 trial

  42. Ponatinib

    Takeda

    Pediatric Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia (Ph+ALL)

    phase 2 small molecule terminated

    1 trial

  43. Ponatinib

    Takeda

    Myeloid Leukemia, Chronic, Chronic Phase

    phase 2 small molecule completed

    1 trial

  44. Ponatinib

    Takeda

    GIST

    phase 2 small molecule completed

    1 trial

  45. Ponatinib

    Takeda

    Chronic Myeloid Leukemia

    phase 2 small molecule completed

    1 trial

  46. Pramlintide+Metreleptin

    Takeda

    Obesity

    phase 2 small molecule terminated

    1 trial

  47. Purified Inactivated Zika Virus Vaccine (PIZV)

    Takeda

    Healthy Volunteers

    phase 2 mab terminated

    1 trial

  48. RECOMBINANT ADAMTS13 (rADAMTS13), -, RITUXIMAB

    Takeda

    Immune-mediated thrombotic thrombocytopenic purpura (iTTP)

    phase 2 small molecule active

    1 trial

Frequently asked questions

How many pipeline programs does Takeda have?

1,179 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This hub lists all published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.

Data attribution: Data sources · All pipeline programs

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.